Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Open-label, Single-arm, Multi-center Study of the Efficacy and Safety of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase II, Open-label, Single-arm, Multi-center Study of the Efficacy and Safety of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Surufatinib (Primary) ; Toripalimab (Primary)
  • Indications Biliary cancer; Carcinoma; Endometrial cancer; Gastric cancer; Neuroendocrine carcinoma; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Hutchison MediPharma; HUTCHMED

Most Recent Events

  • 01 Feb 2025 Results assessing efficacy and safety of this combination regimen in treatment-naive advanced or metastatic non-small-cell lung cancer (NSCLC) patients with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1% or greater (PD-L1-positive) and patients with previously treated small-cell lung cancer, published in the Cancer Immunology Immunotherapy.
  • 07 May 2024 Results (At data cutoff February 28, 2023), published in the Cancer Immunology Immunotherapy
  • 06 Jun 2023 Results (n=28) assessing efficacy and safety of the combination of surufatinib with toripalimab for Chinese patients with endometrial cancer, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top